

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

Phospho-Histone H2A.X (Ser139) (20E3) Rabbit mAb

RRID:AB_2118009

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9718, RRID:AB_2118009

Antibody Information

URL: http://antibodyregistry.org/AB_2118009

Proper Citation: Cell Signaling Technology Cat# 9718, RRID:AB_2118009

Target Antigen: Histone H2A.X, phospho (Ser139)

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-Bond, IHC-P, IF-IC, FC-FP

Consolidation: AB_10121789.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Phospho-Histone H2A.X (Ser139) (20E3) Rabbit mAb

Description: This recombinant monoclonal targets Histone H2A.X, phospho (Ser139)

Target Organism: monkey, rat, mouse, human

Clone ID: clone 20E3

Antibody ID: AB_2118009

Vendor: Cell Signaling Technology

Catalog Number: 9718

Alternative Catalog Numbers: 9718S, 9718P

Record Creation Time: 20260904T193711+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-Histone H2A.X (Ser139) (20E3) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 435 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wu T, et al. (2026) SARM1 executes neuronal parthanatos and promotes excitotoxic cell death. *Neuron*.

Kaddatz H, et al. (2026) Loss of oligodendrocyte transcription factor 2 protein expression in metabolically stressed oligodendrocytes. *Acta neuropathologica*, 151(1).

Goodluck HA, et al. (2026) Glomerular hyperfiltration and enhanced sensitivity to kidney ischemia reperfusion with a blunted KIM-1 response in young male aging-accelerated SAMP8 mice. *American journal of physiology. Renal physiology*, 330(4), F483.

Li C, et al. (2026) ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing. *bioRxiv : the preprint server for biology*.

Xie Y, et al. (2026) Ultraviolet A plays a protective role in ultraviolet B-induced squamous cell carcinoma through c-Fos/XRCC4 axis. *Carcinogenesis*, 47(2).

Wang Q, et al. (2026) FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity. *Molecular cell*.

Pakarinen E, et al. (2026) High-fat diet feeding induces organ-specific vascular remodeling with distinct temporal dynamics in male mice. *Communications biology*, 9(1).

Zhou T, et al. (2026) Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(40), e21541.

Avolio M, et al. (2026) The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer. *Cancer discovery*, 16(2), 270.

Pribyl LJ, et al. (2026) Persistent interferon signaling and clonal expansion mark early events in DNA methylation damage-induced liver cancer. *NAR cancer*, 8(2), zcag014.

Nishinaka T, et al. (2026) IL-4/IL-13 signaling suppresses ABT-263-induced apoptosis in senescent human fibroblasts. *International immunopharmacology*, 184, 116939.

Ishikawa KI, et al. (2026) Suppression of ATM kinase signaling accelerates cellular senescence. *Stem cell reports*, 21(7), 102956.

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. *Cancer research*, 86(11), 2660.

Zhang M, et al. (2026) Lamin A/C safeguards replication initiation by orchestrating chromatin accessibility and PCNA recruitment. *Cell reports*, 45(3), 117075.

Young TM, et al. (2026) CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. *Cancers*, 18(5).

Guo L, et al. (2026) Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA-binding proteins with prion-like domains. *Molecular cell*, 86(1), 114.

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. *Cell reports*, 45(1), 116784.

Ballarò R, et al. (2026) Aerobic Exercise Activates S1PR1 Signaling in Tumor Endothelial Cells to Promote Vascular Function in Pancreatic Cancer. *Cancer research*.

Luo YN, et al. (2026) Tracking mobilization uncovers an evolutionarily conserved mechanism in suppressing mobile genetic elements. *Molecular cell*, 86(12), 2263.

Wang L, et al. (2026) ACSS2 is required for colorectal cancer progression and a druggable target for colorectal cancer treatment. *iScience*, 29(8), 116860.